Deal Details

NanoString Completes $200 Million Convertible Notes Offering

Healthcare

NanoString convertible notes offering

Summary

NanoString Technologies, Inc. (“NanoString” or the “Company”) (NASDAQ:NSTG) recently completed an upsized offering pursuant to Rule 144A of $200 million aggregate principal amount of 2.625% Convertible Senior Notes due 2025. In addition, NanoString has granted to the initial purchasers of the notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of notes.

Baird served as co-manager on this offering.

About

NanoString is a leading provider of life science tools for translational research. The Company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 3,200 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The Company’s GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. NanoString is headquartered in Seattle, Washington.

Healthcare

NanoString convertible notes offering